The supplement patch company Barrière has announced two new products: a motion sickness patch and what it describes as the first lactose intolerance patch to reach the consumer market.
The flagship launch, branded "Dear Dairy," delivers 9000 FCC of lactase enzyme transdermally throughout the day. The company has said that it will debut in 1700 Walmart locations in the US.
Designed as a single daily-wear patch, the company has positioned the product as a hands-free alternative to per-meal enzyme capsules such as Lactaid, targeting dairy-sensitive consumers seeking more convenient digestive health solutions.
Barrière also reports that in an in-home consumer study, more than 85% of users reported minimal digestive discomfort two to four hours after consuming dairy.
The firm's transdermal delivery mechanism uses ultrasmall vitamin and enzyme particles, relying on body heat to drive absorption through the skin and into the bloodstream.
Each patch is claimed to remain active for up to 12 hours and the "Dear Dairy" formulation is vegan, latex-free, filler-free, paraben-free and third-party tested.
CEO and co-founder Cleo Davis-Urman told CNBC that the Walmart partnership was a deliberate channel strategy rather than broad distribution.
The retailer's rapidly growing digestive health aisle made it the appropriate debut point for the lactose patch, she said, distinct from Barrière's existing presence in Target, where the customer skews more beauty and skincare-focused.
"Finding the right partner for the right product is really critical," Davis-Urman said.
Things that we know are working for that customer is how we differentiate so that we're not oversaturating and we're not diluting our brand.
The launch marks a significant milestone in retail scaling. Barrière has grown from around 600 stores in Q2 2025 to more than 6000 in Q2 2026.
The company projects 2026 revenues of $10m — double its 2025 figure — against a current valuation of $19m.
Products are manufactured in the UK under what Davis-Urman describes as the strictest possible regulatory standards under the UK equivalent of the FDA, a positioning the company uses to signal quality to health-conscious consumers in an otherwise largely unregulated US supplement market.
The digestive health opportunity is significant: lactose intolerance affects an estimated 68% of the global population and the transdermal delivery format (if it can substantiate enzyme bioavailability claims at scale) could represent a meaningful formulation shift for the digestive supplement category.